Physician profile
Gregory Ogunnowo
NPI 1881044972
$27,680.98
in general payments reported to CMS, 2019-2025
9 companies · $1,931 in 2025
The $1,931 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,131 · 2022: $269 · 2023: $3,404 · 2024: $20K · 2025: $1,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $18K · Food and Beverage: $4,017 · Travel and Lodging: $3,475 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $17,626.43 |
| Food and Beverage | $4,016.83 |
| Travel and Lodging | $3,475.31 |
| Education | $162.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19,886.17 | 2023-2025 | Corevalve Evolut R, Onyx Frontier, Ffrangio |
| Abbott Laboratories | $2,327.31 | 2021-2024 | Optis, Mitraclip, Epic |
| Biotronik INC. | $2,020.42 | 2021-2022 | |
| Edwards Lifesciences Corporation | $1,946.36 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $1,126.43 | 2023 | |
| Heartflow, INC. | $256.23 | 2023 | Ffrct |
| Janssen Pharmaceuticals, INC | $98.56 | 2022 | |
| Chiesi USA, INC. | $19.50 | 2023 | Kengreal |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ogunnowo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.